688075.SH
安旭生物
SSE · Healthcare · Medical - Specialties · CN
CNY 29.08
−1.59%Year over year
Reported trailing growth
- Revenue
- -22.7%
- EBITDA
- —
- EBIT
- -87.7%
- EPS
- -83.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -58.2%
- EBITDA
- -67.6%
- EBIT
- -73.0%
- Net income
- -71.6%
- EPS
- -71.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026